Celiac Index

The key practical question is not whether gluten is harmful in principle, but how much accidental exposure becomes biologically meaningful over time.

For people with celiac disease, a perfect zero-gluten world does not exist. The real issue is how to think about small, repeated exposures from contamination, labeling limits, restaurant meals, and uncertain food handling.

What the 2007 Microchallenge Trial Found

A classic double-blind 90-day microchallenge study tested adults with biopsy-proven celiac disease who were otherwise on a strict gluten-free-diet. Patients received daily capsules containing 0 mg, 10 mg, or 50 mg gluten.

Main signal:

50 mg/day caused measurable worsening in small-bowel morphology
10 mg/day was less clearly harmful, but not proven completely safe
one patient in the 10 mg/day arm had a clinical relapse

That means the study did not prove that 10 mg/day is harmless. It suggested instead:

50 mg/day is too much as a regular contaminating intake
10 mg/day remains a gray zone

What the 2026 Dose-Response Study Adds

A newer randomized dose-response study approached the threshold question differently. Instead of asking whether months of tiny exposure eventually damage biopsy architecture, it asked whether a single gluten dose triggers a measurable immune reaction within hours.

Its main tool was serum IL-2, an early marker of gluten-specific immune activation.

Main signal:

immune activation could occur at doses below current labeling thresholds
estimated response thresholds were very low at the population level
symptoms were not reliable indicators of low-dose exposure

This does not automatically mean every tiny immune signal causes clinically meaningful long-term damage. But it does mean that the biology can react before patients feel anything and at doses that look trivial on paper.

Why ppm Alone Is Misleading

Patients often hear that “gluten-free” means <20 ppm. But ppm is a concentration, not a total dose.

Real risk depends on:

how contaminated the food is
how much of it is eaten
how often it is eaten

A low-ppm food eaten in small amounts may be trivial. A moderately contaminated food eaten in large amounts every day may not be.

Histology vs Immediate Immune Activation

The two threshold studies answer different questions:

2007 microchallenge study → what repeated daily exposure seems capable of worsening mucosal structure over time
2026 IL-2 study → what single-dose exposure can trigger measurable immune activation within hours

Together they imply an important distinction:

a dose can be biologically active before we know whether it is clinically harmful over months or years
symptoms are a poor guide at low doses
biopsy and acute biomarkers are answering different parts of the same problem

Why <20 ppm Became the Practical Standard

The threshold paper helps explain why <20 ppm became such an important regulatory anchor:

it keeps typical daily intake from specially labeled gluten-free foods well below the clearly harmful 50 mg/day level
it leaves some safety margin for patient-to-patient variability
it recognizes that strict zero contamination is unrealistic in real food systems

So the regulatory threshold is not a claim of perfect biologic safety for every person in every circumstance. It is a practical public-health compromise.

Educational Takeaway

A useful way to think about thresholds is:

direct gluten exposure is the main danger
repeated moderate contamination matters more than imaginary single-molecule traces
dose + frequency + context matter more than ppm in isolation
threshold logic should reduce panic, not justify carelessness

Relationship to Cross-Contamination

Threshold thinking is most useful when combined with gluten-exposure-and-cross-contamination:

restaurants and poorly controlled kitchens matter because they can create meaningful exposure
certified foods matter because they lower repeated-dose burden
oats matter because contamination risk is uneven even when oats themselves may be tolerated

gluten-free-diet | gluten-exposure-and-cross-contamination | oats | management

Source Basis

Current synthesis incorporates:

raw/1-s2.0-S0002916523278806-main.pdf (A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease, 2007)
raw/PIIS0016508526002647.pdf (A Randomized Double-Blind, Placebo-Controlled Dose-Response Study to Assess the Gluten Threshold Dose in Celiac Disease, 2026)